Citi raised its 12-month price target for GlaxoSmithKline to reflect the stock’s recent gains but chose to keep its recommendation at neutral, suggesting the current valuation already incorporates key positives.

The update follows a period of strengthening consumer healthcare revenues and improving margin forecasts, yet Citi warned an absence of fresh catalysts and ongoing pipeline uncertainties could limit further upside.